Aurinia Pharmaceuticals Inc (AUPH) financials
Aurinia Pharmaceuticals revenue and earnings by year
Aurinia Pharmaceuticals's revenue was $283 million in the fiscal year to December 31, 2025, up 20.4% from the year before. Net income was $287 million, 101.5% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 127.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283 | 235 | 176 | 134 | 46 | 50 | 0 | 0 | 0 | 0 |
| Revenue growth | 20.4% | 34.0% | 31.0% | 193.9% | -9.0% | 15660.4% | -31.3% | 10.8% | 141.6% | — |
| Gross profit | 250 | 207 | 161 | 128 | 45 | — | — | — | — | 0 |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | — | — | — | — | 97.7% |
| Operating income | 105 | -5 | -92 | -111 | -181 | -104 | -91 | -55 | -47 | -25 |
| Operating margin | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -11930.9% | -11212.4% | -14466.5% |
| Net income | 287 | 6 | -78 | -108 | -181 | -103 | -88 | -53 | -71 | -23 |
| Net margin | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -11464.1% | -16935.9% | -13465.3% |
| Diluted EPS | $2.08 | $0.05 | -$0.54 | -$0.76 | -$1.41 | -$0.87 | -$0.95 | -$0.62 | -$1.12 | -$0.66 |
| Free cash flow | 135 | 44 | -34 | -80 | -159 | -77 | -64 | -52 | -41 | -19 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AUPH in Markets.
How Aurinia Pharmaceuticals makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $79.4M | 94.9% |
| License Collaboration & Royalty Revenue | $4.28M | 5.1% |
See also: AUPH valuation and P/E history · AUPH returns
No forecast, no recommendation. This page describes Aurinia Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.